Vtv Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
vTv Therapeutics is set to resume its Phase 3 trial for cadisegliatin in Type 1 Diabetes after the FDA lifted a clinical hold, paving the way for further development of the potential adjunctive therapy.
NASDAQ
vTv Therapeutics Inc. released its 10-K filing, detailing financial results and progress in clinical trials, particularly for its lead drug candidate, cadisegliatin, for type 1 diabetes.